Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Lung Cancer Clinical Trials in Nashville | 685 Studies

Clinical Trials Lung CancerNashville

Lung Cancer Clinical Trials in Nashville

Find 685 clinical trials for lung cancer near Nashville, Tennessee. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Nashville

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 241-260 of 685 trials

TerminatedBempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsThis study is to assess the safety and tolerability, and to assess the preliminary clinical benefit of NKTR-214 when combined with pembrolizumab (KEYTRUDA®) with or without…NCT03138889·Fayetteville, Arkansas and 37 others

Lung Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedA Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsThe purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in…NCT02588261·Beverly Hills, California and 166 others

TerminatedStudy of BMS-275183 in Patients With Pre-treated Non-small Cell Lung CancerThe purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC).NCT00099879·Sacramento, California and 19 others

CompletedA Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)This study was to assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the Mesenchymal-epithelial Transition Factor (MET) inhibitor tepotinib combined…NCT03940703·Yuma, Arizona and 178 others

Active not recruitingA Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is planned, in the resectable NSCLC portion.NCT06465329·Orange, California and 46 others

RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus…NCT06875310·Birmingham, Alabama and 316 others

CompletedPhase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaThe primary objectives of this Phase 1b/2 study were as follows: * Phase 1b (Bolus and Infusion): To evaluate the safety and tolerability of carfilzomib in patients with relapsed…NCT00531284·Scottsdale, Arizona and 6 others

CompletedPhase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesA study to assess the activity of tesevatinib in subjects with non-small cell lung cancer (NSCLC) and activating epidermal growth factor receptor (EGFR) mutations who have disease…NCT02616393·Beverly Hills, California and 6 others

CompletedThis Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.This is a study in adults with advanced solid tumors including non-small cell lung cancer.NCT03156114·Miami, Florida and 14 others

TerminatedA Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)This is a first in human, multicenter, open label, Phase 1a and 1b dose-escalation and dose-expansion study to establish the maximum tolerated dose, recommended Phase 2 dose, and…NCT05121948·La Jolla, California and 6 others

Active not recruitingA Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLCThis is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab…NCT05211895·Chandler, Arizona and 225 others

CompletedA Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerThis study will assess the safety and efficacy of avutometinib (VS-6766) monotherapy or VS-6766 in combination with defactinib in subjects with recurrent Non-small cell lung…NCT04620330·Duarte, California and 44 others

CompletedA Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid TumorsThis research study is done to test how well different types of cancer respond to the drug called larotrectinib.NCT02576431·Palo Alto, California and 97 others

TerminatedAzacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors.NCT02959437·Duarte, California and 11 others

TerminatedA Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerTC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes…NCT05451849·San Franciso, California and 6 others

CompletedPulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other DiseasesTo estimate the incidence of Early Onset Pulmonary Events (EOPEs), defined as the proportion of participants with a peak reduction in DLCO of 20% or greater after commencing…NCT03389399·Aurora, Colorado and 4 others

TerminatedAfatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerThis phase I trial studies the side effects and best dose of afatinib and necitumumab and to see how well they work in treating patients with EGFR mutation positive non-small cell…NCT03054038·Duarte, California and 2 others

TerminatedStudy of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung CancerTo compare the efficacy of pegilodecakin in combination with pembrolizumab versus pembrolizumab alone in participants with metastatic non-small cell lung cancer as measured by…NCT03382899·Huntsville, Alabama and 73 others

Active not recruitingA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesThis is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC…NCT06564844·Tucson, Arizona and 89 others

CompletedPhase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung CancerThis is a Phase II, open-label, multicenter, multi cohort, study of VS-6063 (defactinib), a focal adhesion kinase inhibitor, in patients with KRAS mutant non-small cell lung…NCT01951690·Denver, Colorado and 8 others

PreviousPage 13 of 35Next

Other Conditions in Nashville

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma